Requests that FDA determine that the proposed new strength, Ertapenem for Injection, 500 mg/vial, developed by Qilu Antibiotics Pharmaceutical Co., Ltd., is suitable for submission in an Abbreviated New Drug Application (ANDA) | Federal Regulations · Congress.wiki